Daily mindfulness practice with and without slow breathing has opposing effects on plasma amyloid beta levels.
medRxiv : the preprint server for health sciences – March 11, 2025
Source: PubMed
Summary
Engaging in mindfulness meditation with slow breathing can significantly lower plasma amyloid beta (Aβ) levels, a biomarker linked to Alzheimer's disease. In a study involving 60 participants, one week of daily slow breathing meditation led to a reduction in Aβ levels, while normal breathing practices resulted in an increase. The control group, which did not meditate, showed no changes in Aβ levels. These findings highlight the potential of specific breathing techniques in meditation to positively impact brain health and aging.
Abstract
Prior research suggests that meditation may slow brain aging and reduce the risk of Alzheimer's disease (AD). However, we lack research systematically examining what aspect(s) of meditation may drive such benefits. In particular, it is unknown how breathing patterns during meditation might influence health outcomes associated with AD. In this study, we examined whether two types of mindfulness meditation practices - one with slow breathing and one with normal breathing - differently affect plasma amyloid beta (Aβ) relative to a no-intervention control group. One week of daily mindfulness practice with slow breathing decreased plasma Aβ levels whereas one week of daily mindfulness practice with normal breathing increased them. The no-intervention control group showed no changes in plasma Aβ levels. Slow breathing appears to be a factor through which meditative practices can influence pathways relevant for AD.